- Report
- January 2024
- 80 Pages
United Kingdom
From €1365EUR$1,500USD£1,170GBP
From €1365EUR$1,500USD£1,170GBP
- Report
- January 2024
- 147 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Report
- August 2022
United States
From €1766EUR$1,940USD£1,514GBP
- Report
- May 2023
- 105 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- February 2025
- 204 Pages
United States
From €5456EUR$5,995USD£4,677GBP
- Report
- January 2024
- 80 Pages
Poland
From €1365EUR$1,500USD£1,170GBP
- Report
- January 2024
- 80 Pages
Argentina
From €1365EUR$1,500USD£1,170GBP
- Book
- July 2022
- 896 Pages
- Book
- May 2021
- 224 Pages
- Book
- November 2018
- 464 Pages
- Book
- September 2013
- 152 Pages
- Book
- April 2024
- 272 Pages
- Book
- October 2021
North America

Uveitis is a medical condition that affects the uvea, the middle layer of the eye. It is characterized by inflammation of the uvea, which can lead to vision loss and other complications. In the context of optical, uveitis is a major cause of vision loss and can be treated with a variety of treatments, including topical and systemic medications, laser treatments, and surgery.
Uveitis is a growing market in the optical industry, as it is a common cause of vision loss and can be treated with a variety of treatments. Companies in the uveitis market include Bausch + Lomb, Novartis, Allergan, and Santen Pharmaceuticals. These companies offer a range of treatments for uveitis, including topical and systemic medications, laser treatments, and surgery. Show Less Read more